To some it may be a legitimate concern, in my mind its not. In fact, with gleevec going off patent in 2014/15, and sprycel/tasigna potentially moving to first line, a strong case can be made that AP534 doesn't need first line approval to be a success. But just to answer your question, if AP534 is shown to achieve similar/greater CCyR then current treatments but with the advantage of less resistance/progression (due to mutations) then, yes, I think AP534 will eventually be approved as a first line treatment option. In fact for high risk pts (eg those with the T315I mutation) I can easily see a scenario where pts start with 534.
